Pfizer Inc. has a robust portfolio in the biopharmaceutical sector, providing vital medicines and vaccines globally. With solid fundamentals and diversified collaborations, it maintains a strong market presence. However, the current analyst consensus suggests caution in investment.
Pfizer's rating sits at B+, supported by strong cash flow and equity returns but offset by a high debt-to-equity ratio.
| Category | Score | Visualization |
|---|---|---|
| Overall | 3 | |
| Discounted Cash Flow | 5 | |
| Return On Equity | 4 | |
| Return On Assets | 4 | |
| Debt To Equity | 1 | |
| Price To Earnings | 2 | |
| Price To Book | 3 |
Comparing current and past scores highlights the stability in Pfizer's financial health.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-09-03 | 3 | 5 | 4 | 4 | 1 | 2 | 3 |
| Previous | 0 | 5 | 4 | 4 | 1 | 2 | 3 |
The uniform price target from analysts suggests limited growth expectation in the near term.
| High | Low | Median | Consensus |
|---|---|---|---|
| 24 | 24 | 24 | 24 |
Analyst recommendations lean towards holding, indicating a cautious stance on future performance.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 21 | |
| Sell | 1 | |
| Strong Sell | 0 |
Pfizer Inc. maintains a steady financial stance, albeit with a significant debt-to-equity ratio. The consistent price target suggests limited stock movement, and the analyst consensus aligns with a "Hold" recommendation. Investors should consider the robust pipeline of biopharmaceuticals against market saturation and competitive pressures. Overall, a balanced approach with cautious optimism may be warranted given the firm's moderate growth potential.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.